366 related articles for article (PubMed ID: 24341301)
1. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
[TBL] [Abstract][Full Text] [Related]
13. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Katona C; Hansen T; Olsen CK
Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
[TBL] [Abstract][Full Text] [Related]
17. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
19. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
20. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
